ERBB2 and cancer: The results suggested that taking both the cancer cells and immune cells into consideration in the liquid-microenvironment biopsy, EMT-like CTC-WBC clusters may serve as a potential biomarker for prognosis prediction and a rationale target for individualized therapy in HR-positive/HER2-negative metastatic breast cancer patients.